Karin Jooss
Chief Tech/Sci/R&D Officer en GRITSTONE BIO, INC. .
Fortuna: 1 M $ al 31/03/2024
Perfil
Karin Jooss is an Independent Director at Fate Therapeutics, Inc. since 2019.
She is also the Executive VP & Head of Research & Development at Gritstone bio, Inc. since 2021.
Previously, she worked as the Vice President of Research at Cell Genesys, Inc. from 2005 to 2009 and as the Head of Cancer Immunotherapeutics at Pfizer Inc. from 2009 to 2016.
Dr. Jooss holds a doctorate degree from Philipps University of Marburg.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
GRITSTONE BIO, INC.
0.40% | 01/02/2024 | 395 204 ( 0.40% ) | 1 M $ | 31/03/2024 |
FATE THERAPEUTICS, INC.
0.01% | 31/03/2024 | 9 848 ( 0.01% ) | 72 284 $ | 31/03/2024 |
Cargos activos de Karin Jooss
| Empresas | Cargo | Inicio |
|---|---|---|
| GRITSTONE BIO, INC. | Chief Tech/Sci/R&D Officer | 13/04/2016 |
| FATE THERAPEUTICS, INC. | Director/Board Member | 14/03/2019 |
Antiguos cargos conocidos de Karin Jooss.
| Empresas | Cargo | Fin |
|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | 01/04/2016 |
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Chief Tech/Sci/R&D Officer | 01/04/2009 |
Formación de Karin Jooss.
| Philipps University of Marburg | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| PFIZER, INC. | Health Technology |
| FATE THERAPEUTICS, INC. | Health Technology |
| GRITSTONE BIO, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Health Technology |
- Bolsa de valores
- Insiders
- Karin Jooss
